Developer docs
API playgroundTry for free, no card

Search company profiles

Catawba Research

Full company profile

uuid0009sdm

Namestring
Catawba Research
Legal namestring
Catawba Research, LLC
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Catawba Research is a privately held, full-service contract research organization (CRO) founded in 2014 and headquartered in Charlotte, NC, with an offshore operating subsidiary (Catawba Research India) in Mumbai. The company provides clinical trial management services to pharmaceutical, biotechnology, medical device, and formulation development sponsors, executing Phase II-IV studies under ICH-GCP across dermatology, respiratory, women's health, ophthalmology, gastroenterology, and neurology therapeutic areas. Its service portfolio spans Clinical Operations/Full Development Support, Trial Management, and Rater Training, Certification & Endpoint Quality, with a documented regulatory track record of 28 FDA approvals, 4 Health Canada approvals, and 1 DCGI (India) approval and zero FDA Form 483 reports across 42+ audited sites.

Catawba's delivery is organized around "The Catawba Way," a proprietary nimble methodology that supports both end-to-end strategic partnerships and functional service provider (FSP) engagements. The company pairs this with Fixed Model Pricing, a project-based fee structure under which 60% of projects complete with no change orders and 70%+ finish within originally contracted timelines. Supporting technical assets include indication-specific rater training video libraries (30+ minutes of content per therapeutic area), >90% eTMF completeness maintained continuously, and an integrated quality assurance function led by the CSO. Operations span the United States, Canada, Central America/Caribbean, and India, with qualified partner networks extending into Europe, Asia, and Australia.

Catawba generates revenue through professional services fees on multi-year clinical trial contracts, selling directly to enterprise sponsors via a "Request A Proposal" engagement model and supplementing capacity through partnerships (Elligo Health Research for patient access, Bingli for pre-screening, PharmaLegacy for APAC/China preclinical). Customer segments are diversified across large pharma, mid-cap biotech, and specialty formulation developers, with 80% of projects sourced from repeat customers. The company received institutional private equity backing from St. Cloud Capital in October 2020 and has since invested in commercial leadership additions (VPs of Project Management, Global Business Development, and Proposals) to support further scaling.

Short descriptiontext

Catawba Research is a full-service contract research organization providing clinical trial management services to pharmaceutical, biotech, medical device, and formulation development sponsors across dermatology, women's health, ophthalmology, and related therapeutic areas, using a fixed-fee delivery model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCharlotte, United States
HQ citystring
Charlotte
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial services, contract research organization, clinical operations management, regulatory submission support, therapeutic area expertise
Industry1 code
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Research Services
TypeProfessional Services
Description

Catawba Research provides clinical trial management services to pharmaceutical, device, formulation development and biotechnology companies. Revenue is generated through project-based fees using a fixed pricing model. The company manages Phase II-IV clinical trials and receives compensation for regulatory submission support services including NDA, 505(b)(2), and ANDA submissions.

catawbaresearch.com
2Data Management & Support Services (India)
TypeManaged Services
Description

Through Catawba Research India located in Mumbai, the company provides clinical project management, data management, biostatistics and medical writing services as part of its comprehensive CRO offerings.

catawbaresearch.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Fixed Model Pricing - Project-based fixed fee structure
ModelOtherBilling cadenceMulti-year contract
Notes

Fixed pricing model offering predictability and transparency. Customers know total cost upfront with no surprise expenses. 60% of projects completed with no change orders, 80% of change orders are sponsor-driven.

catawbaresearch.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Catawba Research is a full-service contract research organization (CRO) that provides clinical trial management services to pharmaceutical, device, formulation development, and biotechnology companies. The company conducts and manages Phase II-IV clinical trials in accordance with ICH-GCP and applicable regulatory requirements, offering both end-to-end strategic service provider and functional service provider (FSP) delivery models across dermatology, respiratory, women's health, ophthalmology, gastroenterology, and neurology therapeutic areas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 28 FDA approvals and 33 total regulatory approvals achieved
+5 more records
Product overview1 text field

Catawba Research is a full-service Contract Research Organization (CRO) providing clinical trial management services to pharmaceutical, device, formulation development and biotechnology companies. The company operates a unified service model built around three core offerings: Clinical Operations/Full Development Support, Trial Management, and Rater Training/Certification & Endpoint Quality services. The Catawba Way proprietary delivery model unifies these services, enabling both end-to-end strategic partnerships and functional service provider (FSP) arrangements. The company specializes in six therapeutic areas: Dermatology, Respiratory, Women's Health, Ophthalmology, Gastroenterology, and Neurology. Catawba offers a Fixed Model Pricing approach for predictable budgeting. Operations span two headquarters in Charlotte, NC and Mumbai, India, with site networks across the U.S., Canada, Central America/Caribbean, and India, plus partner networks in Europe, Asia, and Australia. The Catawba Research India subsidiary provides dedicated data management, biostatistics, medical writing, and clinical operations services.

Product and service1 record
1Clinical Operations / Full Development Support
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-22
Description

Strategic partnership announced October 22, 2024 to leverage both companies' strengths in driving innovation and excellence in drug development. Provides Catawba Research with new access to China, further expanding their APAC capabilities. This collaboration combines PharmaLegacy's preclinical contract research services with Catawba's clinical trial management expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-06
Description

Partnership to expand access and simplify clinical research participation announced December 6, 2023. Combined capabilities enhance Catawba's ability to provide comprehensive clinical trial services with improved patient access.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mid-size, profitable, full-service CRO running Phase I-IV trials across multiple therapeutic areas with a similar model of cross-functional small teams. Comparable in scale, therapeutic breadth, and target customer profile (small-to-mid biopharma sponsors).

TypeDirect peer
Description

Full-service clinical CRO where Catawba's CEO Andrew Silverman previously served as EVP of Global Operations. Direct competitor in Phase II-IV trial management with overlapping therapeutic-area breadth and similar biopharma/biotech sponsor base.

TypeEmerging player
Description

Tech-enabled clinical research organization focused on expanding trial access. Partnered with Catawba in December 2023, indicating overlapping customer base and complementary capabilities in patient access/recruitment.

TypeBroad incumbent
Description

Global full-service CRO with Phase I-IV clinical trial management. Competes with Catawba for mid-size sponsor business but operates at significantly larger scale and therapeutic breadth.

TypeBroad incumbent
Description

Large global full-service CRO providing Phase I-IV trial management. Provides overlapping capabilities to Catawba but at much larger scale with broader portfolio of services.

TypeDirect peer
Description

Specialty mid-size CRO with therapeutic-area focus (including dermatology, rare disease, CNS, oncology) serving small-to-mid biopharma. Comparable business model and customer profile, especially in dermatology where Catawba has documented depth.

TypeBroad incumbent
Description

Large full-service clinical CRO with Phase I-IV capabilities and central laboratory services. Competes for enterprise CRO contracts that Catawba also targets with its full-service offering.

TypeBroad incumbent
Description

Largest global CRO offering full Phase I-IV clinical trial management across all therapeutic areas. Represents the upper bound of competitive pressure Catawba faces for enterprise pharma contracts.

TypeDirect peer
Description

Specialty CRO with strong focus on 505(b)(2), ANDA, and generic-drug clinical trials, directly overlapping Catawba's regulatory-submission expertise and Phase II/III bioequivalence work.

TypeDirect peer
Description

Mid-size, mid-market-focused CRO providing Phase II-IV clinical trial management with therapeutic-area specialization. Directly comparable in scale and sponsor segment to Catawba.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Catawba Research

Contract Research Organization (CRO) Servicescatawbaresearch.com

Catawba Research is a full-service contract research organization providing clinical trial management services to pharmaceutical, biotech, medical device, and formulation development sponsors across dermatology, women's health, ophthalmology, and related therapeutic areas, using a fixed-fee delivery model.

What Catawba Research does

Catawba Research is a privately held, full-service contract research organization (CRO) founded in 2014 and headquartered in Charlotte, NC, with an offshore operating subsidiary (Catawba Research India) in Mumbai. The company provides clinical trial management services to pharmaceutical, biotechnology, medical device, and formulation development sponsors, executing Phase II-IV studies under ICH-GCP across dermatology, respiratory, women's health, ophthalmology, gastroenterology, and neurology therapeutic areas. Its service portfolio spans Clinical Operations/Full Development Support, Trial Management, and Rater Training, Certification & Endpoint Quality, with a documented regulatory track record of 28 FDA approvals, 4 Health Canada approvals, and 1 DCGI (India) approval and zero FDA Form 483 reports across 42+ audited sites.

Catawba's delivery is organized around "The Catawba Way," a proprietary nimble methodology that supports both end-to-end strategic partnerships and functional service provider (FSP) engagements. The company pairs this with Fixed Model Pricing, a project-based fee structure under which 60% of projects complete with no change orders and 70%+ finish within originally contracted timelines. Supporting technical assets include indication-specific rater training video libraries (30+ minutes of content per therapeutic area), >90% eTMF completeness maintained continuously, and an integrated quality assurance function led by the CSO. Operations span the United States, Canada, Central America/Caribbean, and India, with qualified partner networks extending into Europe, Asia, and Australia.

Catawba generates revenue through professional services fees on multi-year clinical trial contracts, selling directly to enterprise sponsors via a "Request A Proposal" engagement model and supplementing capacity through partnerships (Elligo Health Research for patient access, Bingli for pre-screening, PharmaLegacy for APAC/China preclinical). Customer segments are diversified across large pharma, mid-cap biotech, and specialty formulation developers, with 80% of projects sourced from repeat customers. The company received institutional private equity backing from St. Cloud Capital in October 2020 and has since invested in commercial leadership additions (VPs of Project Management, Global Business Development, and Proposals) to support further scaling.

Catawba Research firmographics

Firmographics
Name
Catawba Research
Legal name
Catawba Research, LLC
Website
https://catawbaresearch.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Catawba Research is a full-service contract research organization providing clinical trial management services to pharmaceutical, biotech, medical device, and formulation development sponsors across dermatology, women's health, ophthalmology, and related therapeutic areas, using a fixed-fee delivery model.
Ownership category
akta.pro rank

Catawba Research industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Clinical trial services
  • Contract research organization
  • Clinical operations management
  • Regulatory submission support
  • Therapeutic area expertise

Where Catawba Research is headquartered

Location

Headquarters

HQ city
Charlotte
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Catawba Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Clinical Research Services: Catawba Research provides clinical trial management services to pharmaceutical, device, formulation development and biotechnology companies. Revenue is generated through project-based fees using a fixed pricing model. The company manages Phase II-IV clinical trials and receives compensation for regulatory submission support services including NDA, 505(b)(2), and ANDA submissions.
  2. Data Management & Support Services (India): Through Catawba Research India located in Mumbai, the company provides clinical project management, data management, biostatistics and medical writing services as part of its comprehensive CRO offerings.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFixed Model Pricing - Project-based fixed fee structure

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Catawba Research product offering

Product offering

Core offering

Catawba Research is a full-service contract research organization (CRO) that provides clinical trial management services to pharmaceutical, device, formulation development, and biotechnology companies. The company conducts and manages Phase II-IV clinical trials in accordance with ICH-GCP and applicable regulatory requirements, offering both end-to-end strategic service provider and functional service provider (FSP) delivery models across dermatology, respiratory, women's health, ophthalmology, gastroenterology, and neurology therapeutic areas.

Product overview

Catawba Research is a full-service Contract Research Organization (CRO) providing clinical trial management services to pharmaceutical, device, formulation development and biotechnology companies. The company operates a unified service model built around three core offerings: Clinical Operations/Full Development Support, Trial Management, and Rater Training/Certification & Endpoint Quality services. The Catawba Way proprietary delivery model unifies these services, enabling both end-to-end strategic partnerships and functional service provider (FSP) arrangements. The company specializes in six therapeutic areas: Dermatology, Respiratory, Women's Health, Ophthalmology, Gastroenterology, and Neurology. Catawba offers a Fixed Model Pricing approach for predictable budgeting. Operations span two headquarters in Charlotte, NC and Mumbai, India, with site networks across the U.S., Canada, Central America/Caribbean, and India, plus partner networks in Europe, Asia, and Australia. The Catawba Research India subsidiary provides dedicated data management, biostatistics, medical writing, and clinical operations services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Operations / Full Development Support

Quantifiable outcome

  • 28 FDA approvals and 33 total regulatory approvals achieved
  • +5 more outcomes

Companies that use Catawba Research

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Catawba Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Catawba Research partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • PharmaLegacy LaboratoriescoreStrategic or Co-development Partner · 22 October 2024Strategic partnership announced October 22, 2024 to leverage both companies' strengths in driving innovation and excellence in drug development. Provides Catawba Research with new access to China, further expanding their APAC capabilities. This collaboration combines PharmaLegacy's preclinical contract research services with Catawba's clinical trial management expertise.
  • Elligo Health ResearchcoreStrategic or Co-development Partner · 6 December 2023Partnership to expand access and simplify clinical research participation announced December 6, 2023. Combined capabilities enhance Catawba's ability to provide comprehensive clinical trial services with improved patient access.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Catawba Research competitors and assessment

Company assessment

Direct peers

  • Medpace: Mid-size, profitable, full-service CRO running Phase I-IV trials across multiple therapeutic areas with a similar model of cross-functional small teams. Comparable in scale, therapeutic breadth, and target customer profile (small-to-mid biopharma sponsors).
  • Syneos Health: Full-service clinical CRO where Catawba's CEO Andrew Silverman previously served as EVP of Global Operations. Direct competitor in Phase II-IV trial management with overlapping therapeutic-area breadth and similar biopharma/biotech sponsor base.
  • Premier Research: Specialty mid-size CRO with therapeutic-area focus (including dermatology, rare disease, CNS, oncology) serving small-to-mid biopharma. Comparable business model and customer profile, especially in dermatology where Catawba has documented depth.
  • Novum Pharmaceutical Research Services: Specialty CRO with strong focus on 505(b)(2), ANDA, and generic-drug clinical trials, directly overlapping Catawba's regulatory-submission expertise and Phase II/III bioequivalence work.
  • Worldwide Clinical Trials: Mid-size, mid-market-focused CRO providing Phase II-IV clinical trial management with therapeutic-area specialization. Directly comparable in scale and sponsor segment to Catawba.

Emerging players

  • Elligo Health Research: Tech-enabled clinical research organization focused on expanding trial access. Partnered with Catawba in December 2023, indicating overlapping customer base and complementary capabilities in patient access/recruitment.

Broad incumbents

  • Parexel International: Global full-service CRO with Phase I-IV clinical trial management. Competes with Catawba for mid-size sponsor business but operates at significantly larger scale and therapeutic breadth.
  • ICON plc: Large global full-service CRO providing Phase I-IV trial management. Provides overlapping capabilities to Catawba but at much larger scale with broader portfolio of services.
  • Labcorp Drug Development (formerly Covance): Large full-service clinical CRO with Phase I-IV capabilities and central laboratory services. Competes for enterprise CRO contracts that Catawba also targets with its full-service offering.
  • IQVIA: Largest global CRO offering full Phase I-IV clinical trial management across all therapeutic areas. Represents the upper bound of competitive pressure Catawba faces for enterprise pharma contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Catawba Research social profiles

Digital presence

Catawba Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Catawba Research leadership team

Management profile

Number of profiles

Profiles8 records

Catawba Research subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Catawba Research funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Catawba Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Catawba Research

What does Catawba Research do?

Catawba Research is a full-service contract research organization (CRO) that provides clinical trial management services to pharmaceutical, device, formulation development, and biotechnology companies. The company conducts and manages Phase II-IV clinical trials in accordance with ICH-GCP and applicable regulatory requirements, offering both end-to-end strategic service provider and functional service provider (FSP) delivery models across dermatology, respiratory, women's health, ophthalmology, gastroenterology, and neurology therapeutic areas.

Is Catawba Research a public or private company?

Catawba Research is a private company. It is classified as private equity controlled and is currently operating.

When was Catawba Research founded?

Catawba Research was founded in 2014. It employs 11 to 50 people.

Where is Catawba Research based?

Catawba Research is headquartered in Charlotte, United States, in the North America region.

How does Catawba Research make money?

Two revenue lines are on record. Clinical Research Services are the primary driver. The others are data Management & Support Services (India).

Who are Catawba Research's main competitors?

Direct peers on record are Medpace, Syneos Health, Premier Research, Novum Pharmaceutical Research Services and Worldwide Clinical Trials. Elligo Health Research is listed as an emerging player. Broad incumbents are Parexel International, ICON plc, Labcorp Drug Development (formerly Covance) and IQVIA.

Does Catawba Research have an API?

No public API is recorded for Catawba Research.

What industry is Catawba Research in?

Catawba Research's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmalegacyCatawba Research Announces Strategic Partnership With PharmaLegacy Laboratories - PharmaLegacyCatawba Research has announced a strategic partnership with PharmaLegacy Laboratories to combine preclinical and clinical research capabilities. This collaboration aims to provide end-to-end drug development solutions and expands Catawba's operational presence in the Asia-Pacific region, specifically China. The joint effort is designed to accelerate the delivery of new therapies by leveraging both entities' specialized expertise.YahooCatawba Research Announces Strategic Partnership With PharmaLegacy LaboratoriesCatawba Research announced a strategic partnership with PharmaLegacy Laboratories to combine preclinical and clinical research services. The collaboration expands Catawba's access to China and APAC capabilities, offering end-to-end drug development solutions. The partnership aims to streamline drug development and accelerate new therapies to market.Business Wire BlogCatawba Research Announces Strategic Partnership With PharmaLegacy LaboratoriesCatawba Research announced a strategic partnership with PharmaLegacy Laboratories to combine preclinical and clinical trial services. The collaboration expands Catawba's access to China and APAC capabilities, offering end-to-end drug development solutions. The partnership aims to streamline drug development and accelerate new therapies to market.Business Wire BlogCatawba Research Celebrates 10 Years of Excellence in Clinical ResearchCatawba Research, a clinical research organization, celebrated its 10-year anniversary, having been founded in 2014. The company expanded its global footprint, welcoming its first team members in Canada and the Netherlands this year. It will host events to commemorate the milestone.Bundy GroupBundy Group served as exclusive advisor to Catawba ResearchBundy Group served as exclusive financial advisor to Catawba Research in a control investment by a life sciences-focused firm. The deal marks the first institutional capital into Catawba Research, supporting its growth as a contract research organization. The partnership aims to accelerate the company's position as a leading international pharmaceutical services provider.PR NewswireSt. Cloud Capital Announces Investment In Catawba ResearchSt. Cloud Capital announced an investment in Charlotte, North Carolina-based Catawba Research, a vertically integrated contract research organization serving pharmaceutical and biotechnology companies globally. The investment comes from St. Cloud's third fund with $250 million in committed capital, with St. Cloud partnering with another financial investment firm focused on control investments in life sciences and industrial sectors. Catawba Research, which provides clinical management services across dermatology, women's health, ophthalmology, and gastroenterology therapeutic areas, aims to become one of the premier global clinical research providers with this support.